p38-MAPK inhibitor VX-745, Purity ≥98%

Synonym: 209410-46-8; VX-745; Neflamapimod; 5-(2,6-Dichlorophenyl)-2-((2,4-difluorophenyl)thio)-6H-pyrimido[1,6-b]pyridazin-6-one; VX 745; VX745; 5-(2,6-Dichlorophenyl)-2-(2,4-difluorophenyl)sulfanylpyrimido[1,6-b]pyridazin-6-one; p38-MAPK inhibitor

MDL: MFCD09834070
CAS Number: 209410-46-8
Compound CID: 3038525

Product Size

5 mg; 10 mg; 25 mg; 50 mg; 100 mg

Price

Datasheet

Datasheet

MSDS

MSDS

Properties

Description

VX-745, soluble in DMSO and insoluble in ethanol and water, targets the ATP-binding site of the kinase, thereby preventing phosphorylation of downstream substrates. It targets p38α and p38β.

Molecular Weight

436.3

Molecular Formula

C₁₉H₉Cl₂F₂N₃OS

Targets

p38α: 10 nM; p38β: 220 nM

Form

Lyophilized powder

Purity

≥98%

Solubility

DMSO: 15 mg/mL (34.38 mM); Water: Insoluble; Ethanol: Insoluble

Identity

Confirmed by NMR/HPLC/MS.

Stability

The product is stable for three years when stored at the recommended temperature in lyophilized powder.

Applications

VX-745 is used to examine the selective inhibition of p38α MAP kinase for therapeutic potential in neuroinflammation and neurodegenerative disorders.

Storage

Store at -20ºC.